PX-1

PX-1 is a synthetic cannabinoid which is found in many synthetic cannabis products. It is also known as 5F-APP-PICA and SRF-30. PX-1 is a potent agonist for the cannabinoid receptors, with a Ki of 2.6 nM at CB1 and 1.2 nM at CB2.

History

PX-1 was first identified in Japan in 2012. It was found in a synthetic cannabis product called "Funky Monkey". Since then, it has been identified in many other synthetic cannabis products around the world.

Pharmacology

PX-1 is a potent agonist for the cannabinoid receptors. It has a Ki of 2.6 nM at CB1 and 1.2 nM at CB2. This makes it more potent than THC, the main active ingredient in cannabis. The effects of PX-1 are similar to those of THC, but can be more intense and longer lasting.

Legal Status

The legal status of PX-1 varies by country. In the United States, it is a Schedule I controlled substance. In the United Kingdom, it is a Class B drug. In Canada, it is a Schedule II drug. In Australia, it is a Schedule 9 drug.

Health Risks

The health risks of PX-1 are not well understood. However, it is known that synthetic cannabinoids can cause a range of adverse effects, including seizures, psychosis, and death. It is also known that PX-1 can be more potent than THC, which suggests that it may carry a higher risk of adverse effects.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• THC

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  PX-1